Abstract
PROSTVAC immunotherapy is a heterologous prime-boost regimen of two different recombinant pox-virus vectors; vaccinia as the primary immunotherapy, followed by boosters employing fowlpox, to provoke immune responses against prostate-specific antigen. Both vectors contain transgenes for prostate-specific antigen and a triad of T-cell costimulatory molecules (TRICOM). In a placebo-controlled Phase II trial of men with minimally symptomatic, chemotherapy-naive metastatic castration-resistant prostate cancer, PROSTVAC was well tolerated and associated with a 44% reduction in death. With a novel mechanism of action, and excellent tolerability, PROSTVAC has the potential to dramatically alter the treatment landscape of prostate cancer, not only as a monotherapy, but also in combination with other novel agents, such as immune check point inhibitors and novel androgen receptor blockers. A Phase III trial recently completed accrual.
Original language | English (US) |
---|---|
Pages (from-to) | 2137-2148 |
Number of pages | 12 |
Journal | Future Oncology |
Volume | 11 |
Issue number | 15 |
DOIs | |
State | Published - Aug 1 2015 |
Keywords
- PROSTVAC
- pox virus immunotherapy
- prostate cancer
ASJC Scopus subject areas
- Oncology
- Cancer Research